Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
Pfizer Japan said on June 5 that it has filed an application seeking a label expansion for its biosimilar version of Rituxan (rituximab), an anti-CD20 antibody, for the treatment of lupus nephritis inadequately controlled with existing therapies. Lupus nephritis is…
To read the full story
Related Article
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
BUSINESS
- Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
- Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…